Starting oral MS medications – how safe are they?
When starting a treatment for multiple sclerosis, many people now opt for an oral medication as an easier, less painful alternative to the older injectable medications. Two therapies – Aubagio and...
View ArticleWhat does “higher efficacy” mean?
For just over a decade, the only medications to treat the MS disease process were the interferon-beta drugs (Avonex, Betaseron/Extavia, Rebif) and Copaxone. These medications had three things in...
View ArticleClik here to view.
Why Gamble with your MS?
Our new infographic tells the story of why it’s important to treat MS – not just to relieve symptoms in the short term, but to try to prevent disability in the years ahead. Controlling inflammation...
View ArticleOcrelizumab: promising results in relapsing and progressive MS
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – A new medication with a novel way of treating multiple sclerosis was the top story...
View ArticleNew information on oral therapies for multiple sclerosis – ECTRIMS 2015
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – Three oral medications are now available to treat multiple sclerosis, and numerous...
View ArticleDoes vitamin D play a role in multiple sclerosis? – ECTRIMS 2015
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – Multiple sclerosis is more common in countries farther away from the equator,...
View ArticleAn update on higher potency treatments for MS – ECTRIMS 2015
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – High-efficacy medications are typically used for people with severe or worsening...
View ArticleAliens inside us – Revisiting the viral theory of multiple sclerosis –...
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – Viruses have long been suspected to be the cause of multiple sclerosis. In fact,...
View ArticleMultiple sclerosis and women’s health – ECTRIMS 2015
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – Women have a 2-3 fold higher risk of developing multiple sclerosis compared to...
View ArticleAre you getting the treatment you need?
European Committee for Treatment and Research in MS (ECTRIMS) – 31st Congress – Barcelona, Spain, October 7-10, 2015 – People with relapsing-remitting MS commonly start treatment with one of the...
View ArticleA trio of new drugs in development for MS
Three new Gilenya spin-offs are currently in development to treat relapsing-remitting (RRMS) and secondary-progressive MS (SPMS), but preliminary results suggest that they may not offer much advantage...
View ArticleLow rate of MS medication use in B.C.
Revised April 25, 2016 Only 1 in 3 people living with multiple sclerosis in the Canadian province of British Columbia has filled a prescription for an immune-modulating medication for their MS. That...
View ArticleUpdate on Oral Medications for MS
American Academy of Neurology (AAN) annual meeting, Vancouver, B.C., April 15-21, 2016 The following are some of the results from studies looking at the effectiveness and safety of oral MS medications....
View ArticleUpdate on Injectable/infusion Medications for MS
American Academy of Neurology (AAN) annual meeting, Vancouver, B.C., April 15-21, 2016 The following are some of the results from studies looking at the effectiveness and safety of injectable and...
View ArticleCanadian Transplant study in MS posts promising results
Click here to view an interview with researcher Dr. Mark Freedman A new Canadian study has reported the most promising results to date for hematopoietic stem cell transplantation (HSCT) in people with...
View ArticleNovel therapy fails in MS trial
Current treatments for multiple sclerosis target different aspects of the immune response in an attempt to reduce inflammation in the brain and spinal cord. This inflammation causes damage to myelin,...
View ArticleNew results from MS medication studies
European Committee for Treatment and Research in MS (ECTRIMS), London UK, September 14-17, 2016 – MS medications have been available for over 20 years but many people are still hesitant about starting...
View ArticleMSology Library – Treatment guidelines
Treatment guidelines – Brain health: Recommendations for improving the diagnosis, management and treatment of MS. Giovannoni and colleagues. Mult Scler Relat Disord 2016;9 Suppl 1:S5-S48....
View ArticleMSology Library – MS therapies
MS therapies Aubagio (teriflunomide). Trial results from two phase III studies. NEW – TENERE study comparing Aubagio with Rebif. Vermersch and colleagues. Mult Scler 2014;20:705-716....
View ArticleMSology Library – Diet
Diet NEW – A scientific review of how the bacteria in your gastrointestinal tract can affect autoimmune disorders such as MS. Forbes and colleagues. Front Microbiol 2016;7:1081....
View Article
